Actio Biosciences develops targeted therapies for rare diseases by utilizing genetic insights to identify specific drug targets linked to single-gene disorders. This approach enhances understanding of disease mechanisms, enabling potential therapeutic applications for more common diseases with shared biological pathways.
Funding
$63M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Developing effective treatments for common diseases is challenging due to the heterogeneity of patient populations and the complex interplay of multiple genes. Identifying high-impact drug targets in these diseases has a low probability of success, hindering drug discovery efforts.
Solution
Actio Biosciences leverages genetic insights from rare, single-gene disorders to identify and validate drug targets that are also relevant in more common diseases. By focusing on rare diseases with well-defined genetic causes, Actio gains a deeper understanding of the target and disease biology. This approach de-risks and guides therapeutic expansion to more prevalent diseases with shared biological pathways, increasing the likelihood of developing effective treatments for both rare and common conditions.
Target Audience
The primary target audience includes patients suffering from rare genetic diseases and individuals affected by more common diseases with shared biological pathways, as well as pharmaceutical companies seeking novel drug targets and therapeutic strategies.
Features
- Focus on identifying drug targets with shared biology between rare and common diseases.
- Utilizes human genetics and precision medicine to develop targeted therapies.
- Applies expertise in genetics, drug discovery, and data sciences to pinpoint drug targets.